MTOR pathway inhibition in renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4, 2012, Pages 356-361

  Pinto Marín, Alvaro ^a   Redondo Sánchez, Andrés ^a   Espinosa Arranz, Enrique ^a   Zamora Auñón, Pilar ^a   Castelo Fernández, Beatriz ^a   González Barón, Manuel ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Everolimus; MTOR; Renal cell carcinoma; Temsirolimus

Indexed keywords

ALPHA INTERFERON; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; TEMSIROLIMUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ASTHENIA; BREAST CANCER; COLORECTAL CANCER; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MUCOSA INFLAMMATION; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84862986202     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.11.008     Document Type: Review

References (40)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Motzer R.J., Hutson T., Tomczak P., et al. Sunitinib vs. interferon α in metastatic renal-cell carcinoma. NEJM 2007, 356:115-124.
3. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. NEJM 2007, 356:125-134.
4. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal-cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
5. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon α, or both, for advanced renal-cell carcinoma. NEJM 2007, 356:2271-2281.
6. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal-cell carcinoma: A randomized, double-blind, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
7. Figlin R.A. Mechanisms of disease: Survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Nat Clin Pract Oncol 2008, 5:601-609.
8. Inoki K., Corradetti M.N., Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005, 37:19-24.
9. Shaw R.J., Cantley L.C. Ras, PI(3)K, and mTOR signaling controls tumor cell growth. Nature 2006, 441:424-430.
10. Dancey J.E. Therapeutic targets: mTOR and related pathways. Cancer Biol Ther 2006, 5:1065-1073.
11. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
12. Kapoor A. Inhibition of mTOR in kidney cancer. Urol Oncol 2009, 16(S1):S33-S39.
13. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1-α expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002, 22:7004-7014.
14. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007, 13:3109-3114.
15. Sarbassov D.D., Guertin D.A., Ali S.M., et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
16. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
17. Patel P.H., Chadalavada R.S., Chaganti R.S., et al. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006, 12:7215-7220.
18. Kapoor A., Figlin R.A. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009, 115:3618-3630.
19. Brenner W., Farber G., Herget T., et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002, 99:53-57.
20. Robb V.A., Karbowniczek M., Klein-Szanto A.J., et al. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007, 177:346-352.
21. Pantuck A.J., Seligson D.B., Klatte T., et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 2007, 109:2257-2267.
22. Sehgal S.N., Baker H., Vezina C. Rapamycin (AY22.989), a new antifungal antibiotic. II. Fermentation, isolation, and characterization. J Antibiot (Tokyo) 1975, 28:727-732.
23. Helliwell S.B., Wagner P., Kunz J., et al. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell 1994, 5:105-108.
24. Brown E.J., Albers M.W., Shin T.B., et al. A mammalian protein target by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758.
25. Sabers C.J., Martin M.M., Brunn G.J., et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995, 270:815-822.
26. Dudkin L., Dilling M., Cheshire P., et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001, 7:1758-1764.
27. Yu K., Toral-Barza L., Discafani C., et al. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001, 8:249-258.
28. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22:1-2.
29. Hidalgo M., Buckner J.C., Erlichman C., et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006, 12:5755-5763.
30. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory cell carcinoma. J Clin Oncol 2004, 22:909-918.
31. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
32. O'Donnell A., Faivre S., Burris H.A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008, 26:1588-1595.
33. Tabernero J., Rojo F., Calvo E., et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26:1603-1610.
34. Jac J., Giessinger S., Khan M., et al. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma. J Clin Oncol 2007, 25(18 suppl):261s.
35. Amato R.J., Jac J., Giessinger S., et al. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma. Cancer 2009, 115:2438-2446.
36. Merchan JR, Pitot HC, Qin R, et al. Phase I/II trial of CCI-779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory patients. J Clin Oncol 20;27(Suppl):15s [Abstract 5039].
37. Patnaik A., Ricart A., Cooper J., et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib, a multitargeted kinase inhibitor in combination with temsirolimus, an mTOR inhibitor, in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2007, 25(Suppl):141s. [Abstract 3512].
38. Patel P.H., Senico P.L., Curiel R.E., et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009, 7:24-27.
39. Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. PNAS 2001, 98:10314-10319.
40. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal cell carcinoma. Lancet Oncol 2009, 10:992-1000.